semaglutide pdufa The FDA has set a date of September 27, 2026, for lirafugratinib, an investigational treatment for patients with FGFR2-altered cholangiocarcinoma. What makes lirafugratinib unique? Unlike multi-kinase inhibitors, it is designed for FDA Warns on Certain Forms

5 A rare but well recognised risk is also the association between desmoplastic melanoma and lentigo maligna, and induration underlying any lentiginous lesion should be thoroughly investigated

Vivarelli, S., Spatari, G., Costa, C., Giamb, F

Glycine, when used as a stabilizer, can actually help extend shelf life by buffering the pH of the solution and protecting the peptide from degradation

A 5mg vial reconstituted with 2ml yields 2.5mg/ml

If sublingual forms prove to be just as effective, they may begin recommending this method over injections, especially for patients who have difficulty with needles

The FDA notes that cancer diagnoses reported during treatment may reflect detection of pre-existing malignancies or represent background incidence rates rather than drug-induced tumors, particularly given the relatively short duration of most treatment courses compared to typical cancer development timelines